Author:
Elawady Tarek,Khedr Alaa,El-Enany Nahed,Belal Fathalla
Subject
Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry
Reference9 articles.
1. Janssen Pharmaceuticals, BALVERSA™ (erdafitinib): US prescribing information, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf (accessed 7 May 2019).
2. FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma (accessed 15 July 2019).
3. Bladder cancer incidence and mortality: A global overview and recent trends;Antoni;Eur. Urol.,2017
4. Fibroblast growth factor receptors as treatment targets in clinical oncology;Katoh;Nat. Rev. Clin. Oncol.,2019
5. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor;Perera;Mol. Cancer Ther.,2017
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献